# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

> **NCT04045028** · PHASE1 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Multiple Myeloma
- Non-Hodgkin Lymphoma
- B-Cell Lymphoma

## Interventions

- **DRUG:** Tiragolumab
- **DRUG:** Daratumumab/rHuPH20
- **DRUG:** Rituximab
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04045028
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-22
- **Primary completion:** 2023-03-28
- **Final completion:** 2023-03-28
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04045028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04045028, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04045028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*